We provide you with 20 years of free, institutional-grade data for LXRX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of LXRX. Explore the full financial landscape of LXRX stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Sullivan Diane E. | Derivatives Exercise | 89,312 | 2026-06-04 | ||
| SOBECKI CHRISTOPHER J | Derivatives Exercise | 89,312 | 2026-06-04 | ||
| Cheung Ivan | Derivatives Exercise | 89,312 | 2026-06-04 | ||
| BARKER SAM L | Derivatives Exercise | 89,312 | 2026-06-04 | ||
| Amouyal Philippe | Derivatives Exercise | 89,312 | 2026-06-04 | ||
| DEBBANE RAYMOND | Derivatives Exercise | 89,312 | 2026-06-04 | ||
| Swain Judith L | Derivatives Exercise | 89,312 | 2026-06-04 | ||
| Artal Participations S.a r.l. | Derivatives Exercise | 20,421,735 | 2026-05-08 | ||
| Martens Rachel Yap | Sale | -35,826 | $1.47 | $52,664 | 2026-03-03 |
| Martens Rachel Yap | Derivatives Exercise | 67,090 | 2026-03-03 | ||
| Granowitz Craig B | Sale | -109,098 | $1.47 | $160,374 | 2026-03-03 |
| Granowitz Craig B | Derivatives Exercise | 312,276 | 2026-03-03 | ||
| Gopinathan Suma | Sale | -24,338 | $1.47 | $35,777 | 2026-03-03 |
| Gopinathan Suma | Derivatives Exercise | 99,950 | 2026-03-03 | ||
| DeFrancesco Lisa | Sale | -74,572 | $1.47 | $109,621 | 2026-03-03 |
| DeFrancesco Lisa | Derivatives Exercise | 152,864 | 2026-03-03 | ||
| Crum Brian T | Sale | -105,019 | $1.47 | $154,378 | 2026-03-03 |
| Crum Brian T | Derivatives Exercise | 273,006 | 2026-03-03 | ||
| Coiante Scott M | Sale | -54,881 | $1.47 | $80,675 | 2026-03-03 |
| Coiante Scott M | Derivatives Exercise | 160,237 | 2026-03-03 | ||
| Exton Michael | Sale | -204,831 | $1.47 | $301,102 | 2026-03-03 |
| Exton Michael | Derivatives Exercise | 503,263 | 2026-03-03 | ||
| McDermott Wendy | Sale | -68,107 | $1.47 | $100,117 | 2026-03-03 |
| McDermott Wendy | Derivatives Exercise | 224,406 | 2026-03-03 | ||
| DEBBANE RAYMOND | Open Market Purchase | 2,000 | $1.49 | 2026-02-27 | |
| DEBBANE RAYMOND | Open Market Purchase | 100,000 | $1.47 | 2026-02-25 | |
| DEBBANE RAYMOND | Open Market Purchase | 150,000 | $1.44 | 2026-02-23 | |
| DEBBANE RAYMOND | Open Market Purchase | 268,497 | $1.31 | 2026-02-18 | |
| Gopinathan Suma | Initial | 2025-06-09 | |||
| SOBECKI CHRISTOPHER J | Derivatives Exercise | 36,810 | 2025-05-13 | ||
| BARKER SAM L | Derivatives Exercise | 36,810 | 2025-05-13 | ||
| DEBBANE RAYMOND | Derivatives Exercise | 36,810 | 2025-05-13 | ||
| Amouyal Philippe | Derivatives Exercise | 36,810 | 2025-05-13 | ||
| Sullivan Diane E. | Derivatives Exercise | 36,810 | 2025-05-13 | ||
| Swain Judith L | Derivatives Exercise | 36,810 | 2025-05-13 | ||
| DeFrancesco Lisa | Sale | -9,096 | $0.67 | $6,094 | 2025-03-03 |
| DeFrancesco Lisa | Derivatives Exercise | 24,673 | 2025-03-03 | ||
| Granowitz Craig B | Sale | -65,308 | $0.67 | $43,756 | 2025-03-03 |
| Granowitz Craig B | Derivatives Exercise | 137,934 | 2025-03-03 | ||
| Crum Brian T | Sale | -45,622 | $0.67 | $30,567 | 2025-03-03 |
| Crum Brian T | Derivatives Exercise | 128,940 | 2025-03-03 | ||
| Alexander Kristen | Sale | -17,862 | $0.67 | $11,968 | 2025-03-03 |
| Alexander Kristen | Derivatives Exercise | 46,430 | 2025-03-03 | ||
| McDermott Wendy | Sale | -30,004 | $0.67 | $20,103 | 2025-03-03 |
| McDermott Wendy | Derivatives Exercise | 98,956 | 2025-03-03 | ||
| MAIN ALAN J | Sale | -43,434 | $0.67 | $29,101 | 2025-03-03 |
| MAIN ALAN J | Derivatives Exercise | 126,814 | 2025-03-03 | ||
| Artal Participations S.a r.l. | Initial | 2024-12-16 | |||
| Artal International S.C.A. | Derivatives Exercise | 57,546,100 | 2024-05-14 | ||
| DEBBANE RAYMOND | Derivatives Exercise | 8,032 | 2024-04-29 | ||
| Amouyal Philippe | Derivatives Exercise | 8,032 | 2024-04-29 | ||
| BARKER SAM L | Derivatives Exercise | 8,032 | 2024-04-29 | ||
| SOBECKI CHRISTOPHER J | Derivatives Exercise | 8,032 | 2024-04-29 | ||
| Swain Judith L | Derivatives Exercise | 8,032 | 2024-04-29 | ||
| LEFKOWITZ ROBERT J MD | Derivatives Exercise | 8,032 | 2024-04-29 | ||
| Alexander Kristen | Sale | -11,793 | $2.62 | $30,898 | 2024-02-29 |
| Alexander Kristen | Derivatives Exercise | 29,243 | 2024-02-29 | ||
| WADE JEFFREY L | Sale | -37,691 | $2.62 | $98,750 | 2024-02-29 |
| WADE JEFFREY L | Derivatives Exercise | 97,564 | 2024-02-29 | ||
| McDermott Wendy | Sale | -22,425 | $2.62 | $58,754 | 2024-02-29 |
| McDermott Wendy | Derivatives Exercise | 46,641 | 2024-02-29 | ||
| MAIN ALAN J | Sale | -24,408 | $2.62 | $63,949 | 2024-02-29 |
| MAIN ALAN J | Derivatives Exercise | 67,546 | 2024-02-29 | ||
| Kassler-Taub Kenneth B. | Sale | -24,353 | $2.62 | $63,805 | 2024-02-29 |
| Kassler-Taub Kenneth B. | Derivatives Exercise | 67,400 | 2024-02-29 | ||
| Granowitz Craig B | Sale | -31,265 | $2.62 | $81,914 | 2024-02-29 |
| Granowitz Craig B | Derivatives Exercise | 63,706 | 2024-02-29 | ||
| Crum Brian T | Sale | -25,604 | $2.62 | $67,082 | 2024-02-29 |
| Crum Brian T | Derivatives Exercise | 68,303 | 2024-02-29 | ||
| COATS LONNEL | Sale | -61,371 | $2.62 | $160,792 | 2024-02-29 |
| COATS LONNEL | Derivatives Exercise | 245,080 | 2024-02-29 | ||
| COATS LONNEL | Open Market Purchase | 90,000 | $1.05 | 2023-11-17 | |
| Amouyal Philippe | Open Market Purchase | 200,000 | $1.01 | 2023-11-14 | |
| COATS LONNEL | Open Market Purchase | 10,000 | $1.01 | 2023-11-13 | |
| DEBBANE RAYMOND | Open Market Purchase | 1,000,000 | $1.14 | 2023-10-12 | |
| WADE JEFFREY L | Open Market Purchase | 10,000 | $1.38 | 2023-09-14 | |
| McDermott Wendy | Open Market Purchase | 6,000 | $1.84 | 2023-08-07 | |
| COATS LONNEL | Open Market Purchase | 10,000 | $2.16 | 2023-06-29 |
The information provided in this report about LXRX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Lexicon Pharmaceuticals, Inc(NASDAQ:LXRX) 
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the t...
Website: http://www.lexpharma.com
Founded: 1995
Full Time Employees: 184
Sector: Healthcare
Industry: Biotechnology